Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Weekly News Recap #Phispers
1. 2649467-58-1
2. 2-pyridinecarboxamide, 4-[[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-
3. Suzetrigine [inn]
4. Log73m21h5
5. Schembl23462160
6. Gtpl12630
7. Vx548
8. Ex-a7354
9. Vx-548
10. Compound 7 [wo2021113627a1]
11. Hy-148800
12. Cs-0641183
13. 4-[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- Dimethyl-5-(trifluoromethyl)oxolane-2- Carboxamido]pyridine-2-carboxamide
14. 4-[[(2r, 3s, 4s, 5r)-3-(3, 4-difluoro-2-methoxyphenyl)-4, 5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide
15. 4-[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide
16. 4-[[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-2-pyridinecarboxamide
Molecular Weight | 473.4 g/mol |
---|---|
Molecular Formula | C21H20F5N3O4 |
XLogP3 | 3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 5 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 104 |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 741 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
NDC Package Code : 17337-0437
Start Marketing Date : 2024-10-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50909-1910
Start Marketing Date : 2025-01-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (0.25kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 50909-1910
Start Marketing Date : 2025-01-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (0.25kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 17337-0437
Start Marketing Date : 2024-10-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
About the Company : Mankind Pharma, came into existence in 1986. In 1991, the company was formed into a legal corporation. However, it actively started working as a fully integrated pharmaceutical com...
About the Company : Founded by chemists with years of working experiences in famous CRO companies in China, Excenen Pharmatech experienced in organic chemistry expecially in medicinal chemistry resear...
About the Company : FandaChem, headquartered in Hangzhou, China, is a reputable supplier and exporter of chemicals with a focus on delivering high-quality products. Our expertise lies in exporting a w...
About the Company : Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.is a high-tech enterprise, which is an integration of R & D, producing and custom synthesis. The products quality is assured ...
About the Company : Honour is a leading global Contract Development and Manufacturing Organization (CDMO) as well as a manufacturer of specialty chemicals and ingredients, operating six facilities tha...
Details:
Journavx (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of adult patients with moderate-to-severe acute pain.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Brand Name: Journavx
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 30, 2025
Lead Product(s) : Suzetrigine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Journavx Gains FDA Approval for Acute Pain Treatment
Details : Journavx (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of adult patients with moderate-to-severe acute pain.
Product Name : Journavx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2025
Details:
VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with painful lumbosacral radiculopathy.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Brand Name: VX-548
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2024
Lead Product(s) : Suzetrigine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vertex Announces Phase 2 Results of Suzetrigine for Painful Lumbosacral Radiculopathy
Details : VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with painful lumbosacral radiculopathy.
Product Name : VX-548
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2024
Details:
VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with moderate-to-severe acute pain.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Brand Name: VX-548
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 30, 2024
Lead Product(s) : Suzetrigine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vertex Announces FDA Acceptance of Suzetrigine NDA for Acute Pain Treatment
Details : VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with moderate-to-severe acute pain.
Product Name : VX-548
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 30, 2024
Details:
VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with moderate-to-severe acute pain.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Brand Name: VX-548
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 18, 2024
Lead Product(s) : Suzetrigine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Details : VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with moderate-to-severe acute pain.
Product Name : VX-548
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2024
Details:
VX-548 (suzetrigine) is a selective NaV1.8 inhibitor, which is being evaluated in phase 3 clinical trials for the treatment of moderate-to-severe acute pain.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Brand Name: VX-548
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 30, 2024
Lead Product(s) : Suzetrigine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vertex Announces Positive Results from VX-548 Phase 3 study for Moderate-Severe Acute Pain
Details : VX-548 (suzetrigine) is a selective NaV1.8 inhibitor, which is being evaluated in phase 3 clinical trials for the treatment of moderate-to-severe acute pain.
Product Name : VX-548
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2024
Details:
VX-548 is an investigational oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8. It is under clinical development for the treatment of painful diabetic peripheral neuropathy.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Brand Name: VX-548
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 13, 2023
Lead Product(s) : Suzetrigine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VX-548 is an investigational oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8. It is under clinical development for the treatment of painful diabetic peripheral neuropathy.
Product Name : VX-548
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2023
Details:
VX-548 is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Brand Name: VX-548
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 22, 2022
Lead Product(s) : Suzetrigine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vertex Advances VX-548 in Acute and Neuropathic Pain
Details : VX-548 is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system.
Product Name : VX-548
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2022
Details:
VX-548 was generally well tolerated in both studies. Most adverse events (AEs) were mild to moderate and there were no serious adverse events (SAEs) related to VX-548. Fewer patients discontinued treatment in the mid- and high-dose VX-548 arms than in the placebo group.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Brand Name: VX-548
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2022
Lead Product(s) : Suzetrigine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VX-548 was generally well tolerated in both studies. Most adverse events (AEs) were mild to moderate and there were no serious adverse events (SAEs) related to VX-548. Fewer patients discontinued treatment in the mid- and high-dose VX-548 arms than in th...
Product Name : VX-548
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2022
Details:
The Phase 2 studies are randomized, double-blind, placebo-controlled trials that will evaluate multiple doses of VX-548 in patients with acute pain following bunionectomy surgery or abdominoplasty surgery.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Brand Name: VX-548
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 19, 2021
Lead Product(s) : Suzetrigine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
Details : The Phase 2 studies are randomized, double-blind, placebo-controlled trials that will evaluate multiple doses of VX-548 in patients with acute pain following bunionectomy surgery or abdominoplasty surgery.
Product Name : VX-548
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2021
Regulatory Info : RX
Registration Country : USA
Brand Name : JOURNAVX
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Packaging :
Approval Date : 2025-01-30
Application Number : 219209
Regulatory Info : RX
Registration Country : USA
RLD : Yes
TE Code :
Brand Name : JOURNAVX
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Approval Date : 2025-01-30
Application Number : 219209
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Market Place
Reply
25 Apr 2025
Reply
19 Feb 2025
Reply
17 Feb 2025
Reply
17 Feb 2025
Patents & EXCLUSIVITIES
Patent Expiration Date : 2040-12-04
US Patent Number : 11834441
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219209
Patent Use Code : U-4125
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2040-12-04
Exclusivity Code : NCE
Exclusivity Expiration Date : 2030-01-30
Application Number : 219209
Product Number : 1
Exclusivity Details :
ABOUT THIS PAGE